These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9637308)

  • 41. [Pharmacokinetics of pefloxacin in burn patients].
    Potel G; Meignier M; Touzé MD; Montay G; Drugeon HB; Baron D
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):777-80. PubMed ID: 3309814
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tissue distribution and disposition kinetics of enrofloxacin in healthy and E. coli infected broilers.
    Soliman GA
    Dtsch Tierarztl Wochenschr; 2000 Jan; 107(1):23-7. PubMed ID: 10689795
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Penetration of pefloxacin and its desmethyl metabolite into the uroepithelium after a 800-mg single oral dose in human patients.
    Moreau JL; Royer-Morrot MJ; Lozniewski A; Trackoen G; Delavault P; Royer RJ
    Eur J Clin Pharmacol; 1996; 49(5):401-5. PubMed ID: 8866637
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improvement of norfloxacin oral bioavailability by EDTA and sodium caprate.
    Dos Santos I; Fawaz F; Lagueny AM; Bonini F
    Int J Pharm; 2003 Jul; 260(1):1-4. PubMed ID: 12818805
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral pharmacokinetics and ascitic fluid penetration of pefloxacin in cirrhosis.
    Cardey J; Silvain C; Bouquet S; Breux JP; Becq-Giraudon B; Fourtillan JP; Beauchant M
    Eur J Clin Pharmacol; 1987; 33(5):469-72. PubMed ID: 3480805
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [A comparative study on lomefloxacin and norfloxacin in the treatment of acute uncomplicated cystitis].
    Ohmori H; Kumon H; Suzuki K; Kamidono S; Arakawa S; Ishigami J; Tanaka H; Amano M; Fujita Y; Kanemasa Y
    Jpn J Antibiot; 1989 Apr; 42(4):1025-50. PubMed ID: 2671424
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Laboratory and clinical studies on norfloxacin in the pediatric field].
    Toyonaga Y; Koizumi M; Imai H; Sakaguchi N; Sugita M; Fukushima Y; Yamasaki M
    Jpn J Antibiot; 1990 May; 43(5):808-25. PubMed ID: 2391752
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Absorption of ciprofloxacin and norfloxacin when administered as niosome-encapsulated inclusion complexes.
    D'Souza SA; Ray J; Pandey S; Udupa N
    J Pharm Pharmacol; 1997 Feb; 49(2):145-9. PubMed ID: 9055185
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chronic dose urinary and serum pharmacokinetics of norfloxacin in the elderly.
    Kelly JG; Deaney NB; Lavan J; Noel J
    Br J Clin Pharmacol; 1988 Dec; 26(6):787-90. PubMed ID: 3242584
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Intraocular penetration of a new quinolone in humans: pefloxacin].
    Bron A; Talon D; Delbosc B; Estavoyer JM
    Bull Soc Ophtalmol Fr; 1987 Nov; 87(11):1261-2, 1265-8. PubMed ID: 3482788
    [No Abstract]   [Full Text] [Related]  

  • 51. [Laboratory and clinical studies of norfloxacin in pediatric field].
    Nishimura T; Tabuki K; Aoki S; Takagi M
    Jpn J Antibiot; 1990 May; 43(5):860-71. PubMed ID: 2391757
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Human and animal studies on the pharmacokinetics of norfloxacin in renal failure].
    Shimada J; Saito A; Akaba K; Miyahara T; Kusajima H; Uchida H; Irikura T
    Jpn J Antibiot; 1986 Oct; 39(10):2643-50. PubMed ID: 3806953
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes.
    Akkan AG; Mutlu I; Ozyazgan S; Gök A; Yigit U; Ozüner Z; Senses V; Pekel H
    Int J Clin Pharmacol Ther; 1997 May; 35(5):214-7. PubMed ID: 9174877
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Dynamics of fluoroquinolone agents in tear fluid--a comparison of the dynamic in tears of human and rabbit eyes].
    Fukuda M; Murano H; Sasaki K
    Nippon Ganka Gakkai Zasshi; 1994 Aug; 98(8):721-6. PubMed ID: 7942332
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Norfloxacin exhibits negligible serum concentrations after repeated conjunctival instillation in children.
    Drago F; La Manna C; Marino V; Marino A; Emmi I; Reibaldi A
    Br J Clin Pharmacol; 1998 Sep; 46(3):272-4. PubMed ID: 9764971
    [No Abstract]   [Full Text] [Related]  

  • 56. Study of the fluorescence characteristics of norfloxacin in reversed micelles and application in analysis.
    Liu Z; Huang Z; Cai R
    Analyst; 2000 Aug; 125(8):1477-81. PubMed ID: 11002931
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of pefloxacin after repeated intravenous and oral administration (400 mg bid) in young healthy volunteers.
    Frydman AM; Le Roux Y; Lefebvre MA; Djebbar F; Fourtillan JB; Gaillot J
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():65-79. PubMed ID: 3458699
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pharmacokinetics and clinical studies of norfloxacin in the pediatric field].
    Motohiro T; Yoshinaga Y; Tsumura N; Oki S; Sasaki H; Aramaki M; Oda K; Kawakami A; Koga T; Shimada Y
    Jpn J Antibiot; 1990 May; 43(5):901-17. PubMed ID: 2202843
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Therapeutic efficacy of norfloxacin for experimental osteomyelitis in rabbits].
    Okada J; Kaetsu M; Aijima H
    Jpn J Antibiot; 1992 May; 45(5):502-6. PubMed ID: 1512935
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of Shiga-like toxin II from Escherichia coli O157:H7 on intestinal clearance of norfloxacin in rats.
    Nakayama H; Kitaichi K; Kanazawa H; Ando M; Fujimoto Y; Takagi K; Takagi K; Hasegawa T
    Life Sci; 2006 Mar; 78(17):1967-74. PubMed ID: 16280134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.